Cliramitug shows promise in cardiac amyloidosis

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease in which misfolded transthyretin proteins accumulate in the heart, leading to structural and functional impairment. Current therapies mainly aim to slow further amyloid formation, while approaches that actively remove existing deposits are an emerging therapeutic strategy.

Long-term results of first-in-human trial on cliramitug, a monoclonal antibody designed to target and remove misfolded transthyreti, have recently been published in Nature Medicine. The study was first-authored by Dr. Peter C. Kahr and shwed encouraging results in 23 patients followed for a median of 29.3 months. Continued treatment was well tolerated and was associated with further reductions in cardiac amyloid burden on cardiac MRI and scintigraphy. Improvements were also observed in cardiac biomarkers, left ventricular relaxation and wall thickness, as well as measures of quality of life. The findings support the potential of amyloid-depleting therapy for ATTR-CM, although larger studies are needed to determine whether these changes translate into improved clinical outcomes.

Read the full research article here